Article Text

The application and mechanism of PD pathway blockade for cancer therapy
  1. Xing Wang1,
  2. Shan Huang2,
  3. Ya Zhang3,
  4. Lin Zhu4,
  5. Xiaoliang Wu5
  1. 1 Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  2. 2 State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
  3. 3 State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China
  4. 4 Department of Oncology, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, China
  5. 5 Department of Oncology, Guizhou Provincial People’s Hospital, Guiyang, China
  1. Correspondence to Dr Lin Zhu, Departmentof Oncology, Affiliated Hospital of Zunyi Medical College, 149 Dalian Road, Zunyi, China; zhulinzl1966{at} and Dr Xiaoliang Wu, Department of Oncology, Guizhou Provincial People’s Hospital, 83 Zhongshan East Road, Guiyang, China; wxlzzly2{at}


Research in cancer therapeutics has achieved major progress in the understanding of the tumour-immunity cycle, which controls the delicate balance between the immune system and tumour. Identification of cancer cell T-cell inhibitory signals, including PD-L1, has generated novel insight into how to reinvigorate the patients’ immune cells to respond to a variety of tumour types. PD-1 and PD-L1 (PD) inhibitory pathway blockade appears to a highly promising therapy and could accomplish durable anti-tumour responses with a reasonable toxicity profile. Some of the FDA-approved mAbs can reverse the negative regulators from tumour cells and antigen presenting cells of T-cell function to treat some cancer types by blocking the PD signalling pathway,especially advanced solid tumours. Emerging clinical data suggest that cancer immunotherapy will become a significant part of the clinical treatment of cancer.

  • immunology

Statistics from


  • XW and SH contributed equally,

  • LZ and XW contributed equally.

  • Contributors XW, SH and YZ wrote the manuscript, LZ and XLW reviewed and edited the final manuscript.

  • Funding Xiaoliang Wu was supported by Guizhou Provincial People’s Hospital Youth Funding (No.GZSQN [2016]20), and Lin Zhu was supported by Guizhou Province Science and Technology Cooperation Funding (No. QKH.LH[2016]7482) and Youth Technology Talent Growth Project of Guizhou Province Education Bureau (No.KY[2016]206).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Authors agree to share all data. Please contact the corresponding authors.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.